Understand FDA changes in terms of your exact products.
Product-level FDA monitoring, delivered to your inbox. Which of your products are affected — by name and ingredient — with the analysis and action items already written.
From: Policy Canary <alerts@policycanary.io>
Your Marine Collagen Powder — Action Required
March 4, 2026 · 7:14 AM
Marine Collagen Powder
The FDA cited three companies for identity-testing failures on marine-sourced collagen in the last 90 days. Your product's ingredient profile matches the cited substances. Lab protocols need updating.
Action Items
- Verify identity-testing protocols for marine collagen
- Request updated CoA from supplier
- Document compliance review for FDA inspection readiness
Deadline
Q2 2026
Source
21 CFR 111.75(a)(1)(ii)
THE DIFFERENCE
Every FDA action.
Matched to your products.
Not summaries — product intelligence. Each card shows what Policy Canary actually delivers to your inbox.
Email Intelligence
Intelligence delivered, not searched for
Every alert arrives in your inbox, scoped to your products — with the analysis and action items already written.
From: Policy Canary
Your Marine Collagen Powder — Action Required
Marine Collagen Powder
Identity-testing warning mapped to your ingredient profile.
Action required by Q2 2026
21 CFR 111.75(a)(1)(ii)
Ingredient Match
Matched by formula
We match FDA actions to your actual ingredients — not just product categories.
Matched to FDA Warning Letter WL-2025-1847
Speed
FDA to inbox in hours
Our pipeline ingests every publication the same day.
FDA publishes
Oct 14
Pipeline ingests
Oct 14
Your inbox
<24h
Dashboard
Every product at a glance
One view. All your products. Color-coded status.
Monitored Products
Marine Collagen Powder
BHA Eye Cream SPF 15
Biotin Complex 5000mcg
Coverage
7 FDA data sources
Federal Register, guidance documents, warning letters, import alerts, Regulations.gov, openFDA, and RSS — all in one pipeline.
Federal Register
847
Warning Letters
1,247
openFDA
169K
Guidance Docs
2,761
Import Alerts
154
Regulations.gov
1,178
RSS Feeds
12
WHEN YOU NEED TO DIG DEEPER
Your dashboard is here
when you need it.
The intelligence starts in your inbox. When you want to explore further — search enforcement history, manage products, see the full picture — your dashboard is ready.
app.policycanary.com/products
Monitored Products
Marine Collagen Powder
NovaBiotics failed identity testing for marine collagen. COA-only documentation was deemed insufficient by the FDA. Your product uses the same ingredient — this warning applies to your formulation.
Recommended Actions
- 1Audit identity testing protocols against 21 CFR 111.75(a)(1)(ii)
- 2Verify COA includes marine collagen-specific identity tests, not generic protein analysis
- 3Confirm per-batch testing with your contract manufacturer
Action required by Q2 2026
Source: FDA CFSAN Warning Letters · 21 CFR 111.75(a)(1)(ii)
Interactive demo · click any product to see its intelligence
WEEKLY INTELLIGENCE
The FDA This Week
Jun 22–Jun 26, 2026
Unapproved sexual health and prostate drugs sold via e-commerce triggered enforcement actions against Amazon.com and multiple specialty retailers. The agency simultaneously finalized nine harmonized guidances establishing effectiveness standards for veterinary anthelmintic drugs across livestock and companion animal species. Food and device sectors saw critical actions, including Class I recalls for GE HealthCare resuscitation systems and multiple Foreign Supplier Verification Program violations.
International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: General Recommendations; Guidance for Industry; Availability
The FDA is announcing the availability of a final guidance for industry titled 'Effectiveness of Anthelmintics: General Recommendations' (VICH GL7). This guidance, developed by the VICH, provides recommendations for the design and conduct of clinical trials to demonstrate the effectiveness of anthelmintic medicinal products in various animal species.
Amazon.com, Inc. — Unapproved New Drugs/Misbranded
Amazon.com, Inc.
The FDA issued a Warning Letter to Amazon.com, Inc. for distributing unapproved new drugs via its Fulfillment by Amazon (FBA) network. The products, marketed for the treatment of phimosis and balanitis, are classified as unapproved new drugs because they make disease treatment claims without having an approved FDA application or complying with the relevant OTC monograph.
Huons Co., Ltd. — CGMP/Finished Pharmaceuticals/Adulterated
Huons Co., Ltd.
FDA issued a Warning Letter to Huons Co., Ltd. for severe CGMP violations at its South Korean drug manufacturing facility. Violations include egregious data integrity breaches in the microbiology lab (such as discarded failing bioburden plates and backdated records), inadequate out-of-specification investigations, and severe contamination hazards in aseptic processing operations. Consequently, the firm was placed on Import Alert 66-40, suspended U.S. production, and committed to a voluntary recall of all unexpired drugs in the U.S. market.
Pamex Foods Incorporated — Foreign Supplier Verification Program (FSVP)
Pamex Foods Incorporated
The FDA issued a Warning Letter to Pamex Foods Incorporated for failing to comply with Foreign Supplier Verification Program (FSVP) requirements (21 CFR part 1, subpart L). The firm did not develop an FSVP for imported foods, including Worcestershire sauce, frozen stuffed corn tortillas, and corn flour. Furthermore, the firm failed to register its facility as required under section 415 of the FD&C Act. The FDA gave the firm 15 working days to respond and warned that continued non-compliance could lead to the imported foods being placed on Detention Without Physical Examination (DWPE).
Don't miss the next briefing.
The weekly FDA digest for product teams. Free. No account required.
WHO IT'S FOR
You don't have a regulatory team.
You have Policy Canary.
Whether you're the founder, the quality lead, or the person who gets the call when something goes wrong — you need product-level answers, not regulatory summaries.
Founder / CEO
32 SKUs · 40+ active ingredients
“Which of my 32 SKUs is affected? I can’t cross-reference 40+ ingredients manually after every FDA notice.”
QA Manager
Moisturizer line · Next audit: Q2 2026
“Does the new BHA guidance apply to our moisturizer line? I need to know before our next audit.”
Product Manager
Q3 launch timeline · Collagen SKU at risk
“What does this collagen identity testing warning mean for our Q3 launch timeline?”
VP Regulatory
47 products · 3 categories
“I have 47 products. Show me which ones are affected — not a 500-page Federal Register summary.”
Don't find out from a recall notice.
Your Marine Collagen Powder. Your BHA Eye Cream. Monitored by name, matched by ingredient, matched against every FDA change.
Your products monitored by name and ingredient
Action items with deadlines, not summaries
Every claim linked to the source document
All-clear confirmation when nothing affects you
The FDA cut 3,859 employees. Enforcement is less predictable, not more.
7
FDA data sources
<24 hrs
pub to email
169K
substances indexed
How many products?
5Monthly Cost
$99
Included Products
5
Base Plan
Total: $99/mo
Includes 5 products
Full access included. No data caps. Cancel anytime.